Patents Represented by Attorney, Agent or Law Firm P. H. Ginsburg
-
Patent number: 6552015Abstract: The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.Type: GrantFiled: August 1, 2001Date of Patent: April 22, 2003Assignee: Pfizer Inc.Inventors: Anton Franz Joseph Fliri, Todd William Butler, Randall James Gallaschun
-
Patent number: 6548502Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder, such as pathological gambling, attention deficit disorder with hyperactivity disorder and sex addiction, comprising administering a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 26, 2001Date of Patent: April 15, 2003Assignee: Pfizer IncInventors: Stevin H. Zorn, Mark A. Sanner, Antor F. Fliri, Patricia A. Seymour
-
Patent number: 6537995Abstract: A method is provided for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, cluster headache, migraine, pain, obsessive-compulsive disorder, panic disorder, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula (I) or the pharmaceutically acceptable salt thereof; wherein X, Y, Z, R2 and R3 are as defined herein.Type: GrantFiled: May 22, 2001Date of Patent: March 25, 2003Assignee: Pfizer Inc.Inventor: Harry R. Howard
-
Patent number: 6525048Abstract: The present invention relates to compounds of the formula These compounds are useful as psychotherapeutic agents.Type: GrantFiled: January 18, 2000Date of Patent: February 25, 2003Assignee: Pfizer Inc.Inventor: Gene Michael Bright
-
Patent number: 6525196Abstract: The present invention relates to compounds of formula 1, wherein R1, R2, R3 and R4 are defined as in the specification. These compounds are useful as psychotherapeutic agents.Type: GrantFiled: December 6, 1999Date of Patent: February 25, 2003Assignee: Pfizer Inc.Inventors: Gene M. Bright, Kishor A. Desai
-
Patent number: 6521630Abstract: The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): pharmaceutically acceptable salts thereof, wherein A is (CH2)n where n is equal to 0, 1 or 2; U is CH2, NH, or NR3, R1 and R2 are selected independently from H, (C1-C6)alkyl, Cl, F, CN, nitro, CF3, —NHC(O)R6 and —OR7, or R1 and R2, together with the atoms to which they are attached, form a carbocyclic or heterocyclic five- or six-membered ring, R3 is selected from the group consisting of H, (C1-C6)malkyl, C(═O)—(C1-C6)alkyl, where m=1 or 2; R4 and R5 are selected from H, (C1-C6)alkyl, Cl, F, —CF3, —CN, —NHC(═O)R6, —OR7, a 5-to 7-membered aryl or heteroaryl ring, where m, R6 and R7 are as defined above; and R6 and R7 are selected independently from H, (C1-C6)alkyl or a 5- to 7-membered aryl or heteroaryl ring; V is CH, CR3, or N; W is CH2, C(O), or S(O)2; X is C or N; and Y is CH, CR1,CR2, or N.Type: GrantFiled: August 29, 2000Date of Patent: February 18, 2003Assignee: Pfizer Inc.Inventors: Anton Franz Joseph Fliri, Todd William Butler, Randall James Gallaschun, John Anthony Ragan, Brian Patrick Jones
-
Patent number: 6518282Abstract: There is provided a compound of formula I, wherein R1, R2, R3 and R4 have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.Type: GrantFiled: May 23, 2000Date of Patent: February 11, 2003Assignee: Pfizer Inc.Inventors: Stephen Paul Gibson, Ivan Tommasini
-
Patent number: 6506780Abstract: This invention relates to a series of substituted benzophenone and sulfone compounds of the formula I wherein ring A, Z, Y, R and X are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.Type: GrantFiled: July 2, 2001Date of Patent: January 14, 2003Assignee: Pfizer Inc.Inventor: John A. Lowe, III
-
Patent number: 6476042Abstract: The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1 receptor agonist with caffeine and a cyclooxygenase-2 (COX-2) inhibitor.Type: GrantFiled: June 26, 2000Date of Patent: November 5, 2002Assignee: Pfizer Inc.Inventor: Wilma M. Harrison
-
Patent number: 6465478Abstract: A compound of formula: R1 and R2 are independently C1-C4 alkyl; or R1 and R2, taken together with the carbon atom to which they are attached, form a mono-, bi-, tri- or spiro-cyclic group having 3 to 13 carbon atoms, wherein the cyclic group is optionally substituted by one to five substituents; A is (C1-C3)alkyl, phenyl, benzyl or the like; R is hydrogen, (C1-C3)alkyl, amino-(C1-C6)alkyl, heterocyclic-(C1-C3)alkyl wherein the heterocyclic is optionally substituted by amino, ((C1-C4)alkyl)-Z—(C1-C6)alkyl wherein Z is OC(═O) or the like; and X is (C1-C3)alkyl, phenyl or the like. These compounds are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.Type: GrantFiled: October 22, 1999Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: Fumitaka Ito, Yoriko Ohashi
-
Patent number: 6465500Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R3 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR3, —CO2R8, —CONR9R10, —OR3, —SO2NR9R10, or —S(O)4R9; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkType: GrantFiled: October 23, 2000Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6462035Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: August 7, 2000Date of Patent: October 8, 2002Assignee: Pfizer Inc.Inventor: Jotham Wadsworth Coe
-
Patent number: 6462048Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: September 24, 1998Date of Patent: October 8, 2002Assignee: Pfizer Inc.Inventor: Harry R. Howard
-
Patent number: 6455567Abstract: The invention provides the use of a compound of formula (I) wherein R1 and R2 independently represent H or C1-C6 alkyl, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of dermatological disorders; peripheral neuropathies; arthritis; gastrointestinal or urogenital diseases; headache associated with substances or their withdrawal; tension headache; pediatric migraine; post-traumatic dysautonomic cephalgia; orofacial pain; allergic or chronic obstructive airways diseases; glaucoma or ocular inflammation; or prophylaxis of migraine.Type: GrantFiled: January 27, 2000Date of Patent: September 24, 2002Assignee: Pfizer Inc.Inventors: Kathryn Louise Monkhouse, Paul Gupta, Shirley Jones, Juan Lahuerta, Gillian Christine Land, Susan Frances Robson, Gillian Mary Samuels, Alan Brian Wilson, Martin James Wythes
-
Patent number: 6441192Abstract: The present invention is concerned with the acylation of indoles, specifically the preparation of 3-acylated indoles which may be further treated to provide indoles having an alternative substituent at the 3-position.Type: GrantFiled: September 25, 2000Date of Patent: August 27, 2002Assignee: Pfizer Inc.Inventor: Jolyon Francis Perkins
-
Patent number: 6436957Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or -Q-R4; R2 and R3 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR9, —CO2R9, —CONR9R10, —OR9, —SO2NR9R10, or —S(O)qR9; R8 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkyl-aryl; q iType: GrantFiled: October 23, 2000Date of Patent: August 20, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6410739Abstract: Compounds of the formula where W is are particularly useful in treating migraine and other disorders, such as depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders. The compounds can also be used as centrally acting antihypertensives and vasodilators.Type: GrantFiled: October 23, 2000Date of Patent: June 25, 2002Assignee: Pfizer INCInventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6333326Abstract: This invention relates to 2,3(1H,4H)-quinoxalinedione derivatives which are selective antagonists of N-methyl-D-aspartate receptors. More particularly, this invention relates to 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and to the preparation of, compositions containing, and the uses of, such derivatives. It also relates to a method for treating acute neurodegeneration disorders and chronic neurological disorders.Type: GrantFiled: August 2, 1999Date of Patent: December 25, 2001Assignee: Pfizer IncInventors: Alan Stobie, Elisabeth Colette Louise Gautier, David Charles Waite, Robert James Crook
-
Patent number: 6284757Abstract: This invention relates to the use of compounds of formula I wherein R1, R2, R3, X, m and n are defined as in the specification, and their pharmaceutically acceptable salts, for the treatment of disorders of the serotonin system.Type: GrantFiled: August 11, 1999Date of Patent: September 4, 2001Assignee: Pfizer Inc.Inventor: Mark Allen Sanner
-
Patent number: 6258953Abstract: Compounds of the formula wherein R1, R2, R3, R4, R5 and X are defined as in the specification. These compounds are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and antagonists.Type: GrantFiled: May 28, 1997Date of Patent: July 10, 2001Assignee: Pfizer Inc.Inventors: Harry Ralph Howard, Barbara Eileen Segelstein